# age1

> age1 is a VC fund in San Francisco backing Biotechnology and Pharmaceutical. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 6
- Last investment: Feb 2026
- Lead investor: 50%
- Last updated: Aug 2026
- Website: https://age1.com/

age1 is a VC fund in San Francisco focused on Biotechnology and Pharmaceutical. Longevity is at an inflection point. Due to scientific advances over the last 30 years, we are beginning to change how we interact with chronological age, living a longer number of healthy years than ever before. Here and now, we embark on this journey. Longevity Fund is launching Age 1, a 4-month program based in SF which offers both capital andhelp to launch founder-driven biotechnology companies. We are selecting a small group of innovative scientists and technologists who are working to extend human healthspan to bring to San Francisco.

## Contacts

5 contacts available for age1. Shizune tracks 3 team members at age1. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/age-1?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 83% |
| Pharmaceutical | 2 | 33% |
| Pet | 1 | 17% |
| Medical | 1 | 17% |
| Genetics | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 50% |
| Pre-Seed | 1 | 17% |
| Series A | 1 | 17% |
| Series C | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 67% |
| Ireland | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alex Colville | General Partner | 2 | — |
| Laura Deming | Partner | 2 | https://shizune.co/investors/profile/laura-deming-2 |
| Omri Amirav-Drory | Mentor | 16 | https://shizune.co/investors/profile/omri-amirav-drory |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Loyal | Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $100M | Series C | Feb 11, 2026 |  |
| Aerska | Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $39M | Series A | Feb 09, 2026 |  |
| Skeletalis | Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis. | $8M | Seed | Nov 17, 2025 |  |
| Aerska | Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $21M | Seed | Oct 01, 2025 |  |
| General Proximity | General Proximity is a pioneering future-oriented proximity medicine that envisions the future of medicine. | $16M | Seed | Jan 03, 2025 |  |
| Aperture Therapeutics | Aperture Therapeutics is a biotechnology company focused on the development of novel therapies for age-related neurodegenerative diseases. Utilizing a unique drug discovery platform, the company aims to harness the genetic diversity of patients to identify new disease pathways and drug targets. With operations based in a lab incubator, ApertureTherapeutics is in the pre-clinical stage, actively applying insights from neuroscience and immunology to advance its research. The company's approach emphasizes the importance of genetic diversity in the discovery process, aiming to lead to more effective treatments for neurodegeneration and neuroimmunology conditions. |  | Pre-Seed | Feb 01, 2024 |  |

6 of 6 investments shown.

## Co-investors
- [LSP Dementia Fund](https://shizune.co/investors/profile/lsp-dementia-fund) — VC Fund, 2 deals together
- [Ada Ventures](https://shizune.co/investors/profile/ada-vemtires) — VC Fund, 1 deal together
- [BACKED VC](https://shizune.co/investors/profile/backed-vc) — VC Fund, 1 deal together
- [Baillie Gifford](https://shizune.co/investors/profile/baillie-gifford) — VC Fund, 1 deal together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 1 deal together
- [BlueYard Capital](https://shizune.co/investors/profile/blueyard-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does age1 invest in?

age1 invests primarily in Biotechnology, Pharmaceutical and Pet startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact age1?

Public channels for age1 include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at age1?

The team at age1 includes Alex Colville (General Partner), Laura Deming (Partner) and Omri Amirav-Drory (Mentor). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co